Iron overload is the main cause of morbidity and mortality in hereditary hemochromatosis, 2-thalassemia and various anemias that require chronic transfusions. Alternatives to current treatments of iron overload are a high priority, as reflected in a recent NIH initiative (PAS-10-046). Hepcidin deficiency is the direct cause of iron overload in nearly all cases of hereditary hemochromatosis and in ?-thalassemia intermedia, and may contribute to iron overload and maldistribution in ?-thalassemia major. Hepcidin therapy is a rational experimental approach to the prevention and treatment of iron overload in these disorders. Natural hepcidin is expensive, rapidly cleared from circulation and not orally absorbable. We developed 7-9 amino acid peptides, "minihepcidins" that mimic the activity of hepcidin and exceed its potency. Some have been engineered for oral absorption, and have shown considerable activity by oral route in mice. We will determine the potential of minihepcidins to prevent iron overload or reverse its toxic effects in hemochromatosis and ?-thalassemia, and examine the effects of hepcidin agonists on ?-thalassemic erythropoiesis in mouse models and in bone marrow cultures and identify those mechanisms that could ameliorate anemia. Specifically, we will: 1. Select a parenteral and an oral minihepcidin for subsequent studies based on the dose-response relationship and duration of hypoferremic effect in C57BL/6 mice and hepcidin knockout mice. 2. Define the effects of minihepcidins in animal models of hereditary hemochromatosis. a. Can minihepcidins started after weaning prevent the development of iron overload in mouse models of severe (hepcidin knockout) or moderate (HFE knockout) hereditary hemochromatosis? b. Can minihepcidin treatment of mice with established iron overload (hepcidin or HFE knockouts) redistribute iron away from vulnerable cells and tissues (hepatocytes, pancreatic islet cells, cardiomyocytes) to relatively iron-resistant macrophages? c. Can minihepcidins reverse iron overload-related liver damage in the gerbil model of iron-induced hepatic cirrhosis? 3. Define the effects of minihepcidins in animal models of ?-thalassemia. a. Can minihepcidins prevent iron overload in a mouse model of ?-thalassemia intermedia, while improving (or not worsening) anemia? b. Can minihepcidins ameliorate iron overload in transfused mice with ?-thalassemia major and redistribute iron to less vulnerable locations, without worsening anemia? c. Identify mechanisms by which minihepcidins can improve ?-thalassemic erythropoiesis. This project would establish minihepcidins as viable drug leads for further development, and would eventually help patients with iron overload disorders by providing them with improved therapeutic options.

Public Health Relevance

Iron overload diseases are an important medical problem in need of new treatments. Building on recent advances in the understanding of iron metabolism, we propose to develop and test new kinds of medications for the treatment of iron overload in hereditary hemochromatosis and Cooley's anemia. Project Narrative Iron overload diseases are an important medical problem in need of new treatments. Building on recent advances in the understanding of iron metabolism, we propose to develop and test new kinds of medications for the treatment of iron overload in hereditary hemochromatosis and Cooley's anemia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK090554-05
Application #
8713980
Study Section
Special Emphasis Panel (ZRG1-VH-E (02))
Program Officer
Bishop, Terry Rogers
Project Start
2010-09-30
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$553,241
Indirect Cost
$110,147
Name
Weill Medical College of Cornell University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Guimarães, Jacqueline S; Cominal, Juçara G; Silva-Pinto, Ana Cristina et al. (2015) Altered erythropoiesis and iron metabolism in carriers of thalassemia. Eur J Haematol 94:511-8
Kautz, Leon; Nemeth, Elizabeta (2014) Molecular liaisons between erythropoiesis and iron metabolism. Blood 124:479-82
Gardenghi, Sara; Renaud, Tom M; Meloni, Alessandra et al. (2014) Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood 123:1137-45
Crielaard, Bart J; Rivella, Stefano (2014) ?-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis. Int J Biochem Cell Biol 51:89-92
Kautz, Léon; Jung, Grace; Valore, Erika V et al. (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46:678-84
Rodriguez, Richard; Jung, Chun-Ling; Gabayan, Victoria et al. (2014) Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun 82:745-52
Ruchala, Piotr; Nemeth, Elizabeta (2014) The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 35:155-61
Nemeth, Elizabeta; Ganz, Tomas (2014) Anemia of inflammation. Hematol Oncol Clin North Am 28:671-81, vi
Breda, Laura; Rivella, Stefano (2014) Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am 28:375-86
Bystrom, Laura M; Guzman, Monica L; Rivella, Stefano (2014) Iron and reactive oxygen species: friends or foes of cancer cells? Antioxid Redox Signal 20:1917-24

Showing the most recent 10 out of 18 publications